Search

Author/Creator Prosser, Ian

1. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Issue 4 (21st March 2019)

Authors:
Hapgood, Greg; Stone, Janey M.; Zannino, Diana; George, Anup; Marlton, Paula; Prince, Henry Miles; Hui, Chi-Hung; Prosser, Ian; Lewis, Ian D.; Bradstock, Kenneth; Seymour, John F.
Journal:
Leukemia & lymphoma
Issue:
Volume 60:Issue 4(2019)
Page Start:
904
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Issue 2 (1st February 2017)

Authors:
Kenealy, Melita; Patton, Nigel; Filshie, Robin; Nicol, Andrew; Ho, Shir-Jing; Hertzberg, Mark; Mills, Tony; Prosser, Ian; Link, Emma; Cowan, Linda; Zannino, Diana; Seymour, John F.
Journal:
Leukemia & lymphoma
Issue:
Volume 58:Issue 2(2017)
Page Start:
298
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search